Deprim

Χώρα: Νέα Ζηλανδία

Γλώσσα: Αγγλικά

Πηγή: Medsafe (Medicines Safety Authority)

Δραστική ουσία:

Sulfamethoxazole 40 mg/mL; Trimethoprim 8 mg/mL

Διαθέσιμο από:

AFT Pharmaceuticals Ltd

INN (Διεθνής Όνομα):

Sulfamethoxazole 40 mg/mL

Δοσολογία:

40mg/200mg per 5mL

Φαρμακοτεχνική μορφή:

Oral suspension

Σύνθεση:

Active: Sulfamethoxazole 40 mg/mL Trimethoprim 8 mg/mL Excipient: Carmellose sodium Citric acid Dispersible cellulose Glycerol Sodium citrate Polysorbate 80 Ponceau 4R Purified water Raspberry flavour E_0026934 Sodium methyl hydroxybenzoate Sodium propyl hydroxybenzoate Syrup

Μονάδες σε πακέτο:

Bottle, glass, Amber Type III with PP child resistant cap 100 mL., 100 mL

Kατηγορία:

Prescription

Τρόπος διάθεσης:

Prescription

Κατασκευάζεται από:

Virchow Laboratories Limited

Περίληψη προϊόντος:

Package - Contents - Shelf Life: Bottle, glass, Amber Type III with PP child resistant cap 100 mL. - 100 mL - 36 months from date of manufacture stored at or below 25°C

Ημερομηνία της άδειας:

2008-12-04

Αρχείο Π.Χ.Π.

NEW ZEALAND DATA SHEET
1.
DEPRIM
Deprim oral suspension, sulfamethoxazole 200mg and trimethoprim 40mg
per 5mL.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Deprim contains 200 mg Sulfamethoxazole and 40 mg trimethoprim per 5
mL.
Excipients with known effect: For the full list of excipients, see
section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension.
Deprim Suspension is a pink, raspberry flavoured suspension containing
200 mg Sulfamethoxazole and
40 mg trimethoprim per 5 mL.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Deprim has a broad spectrum of antibacterial activity and may be
indicated for the following:
Gastrointestinal tract infections:

Treatment of cholera as an adjunct to fluid and electrolyte
replacement when the organism has
been shown to be sensitive in vitro

Treatment of Shigellosis (may be less effective in some parts of the
world due to resistant
organisms)

Treatment of travellers’ diarrhoea including gastroenteritis due to
enterotoxigenic E. coli

Genital tract infections:

Treatment of gonorrhoea including oro-pharyngeal and ano-rectal
infection

Treatment of chancroid (may be less effective in some parts of the
world due to resistant organisms

Treatment of ganuloma inguinale (venereum)
Urinary tract infections:
Treatment of acute uncomplicated urinary tract infections. It is
recommended that initial episodes of
uncomplicated urinary tract infections be treated with a
singleeffective antibacterial agent rather than
the combination.
Respiratory tract infections:

Treatment of otitis media. Deprim is not indicated for prophylactic or
prolonged administration in
otitis media

Treatment of acute exacerbations of chronic bronchitis

Treatment and prevention of Pneumocystis jirovecii
Other:

Treatment and prophylaxis of toxoplasmosis

Treatment of nocardosis
There are a number of other bacterial conditions caused by sensitive
organisms for which treatment
with Deprim may be appropriate. The use of Deprim should be based on
clinical experience and local
in